Randomized Blinded Evaluation of the Effects of TENS and IFC Compared to a Sham Device and SOC in Patients With Non-Specific CLBP
Completed · Not applicable · NCT05972889
Conditions: Non-Specific Chronic Lower Back Pain
At a glance
- Research payments reported, 2025
- $167,774
- U.S. investigators named
- 1
- Sites paid
- 8
- Planned or actual enrollment
- 334
About the trial
- Sponsor
- Zynex Medical, Inc.
- Tested
- NexWave (device), Sham (device)
- Dates
- Started 2023-11-02; completion 2025-10-21
- Results posted
- Not yet
This is a prospective, sham-controlled, randomized, single-blinded, multi-center study comparing two different modes of the NexWave device, transcutaneous electrical nerve stimulation (TENS) and interferential current (IFC), with an identical non-functioning NexWave sham device or self-defined standard of care for improvement of pain intensity of non-specific CLBP.
From ClinicalTrials.gov, last updated 2025-10-28. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Zynex Medical, Inc. reported $167,774 in research payments for this study in 2025 (9 payments).
Products named: Nexwave
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- The Center for Clinical Research, LLC $64,963
- One Oak Medical Group, LLC $57,774
- Wcg Irb Inc $14,554
- Summit Brain, Spine and Orthopedics $10,130
- $7,778
- Estate Ventures, LLC $6,360
- Dbps Research, LLC $5,465
- Horizon Clinical Research, LLC $500
- Gi P.li $250
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.